newsfilter
← Interviews
a16z13 min

On Machine Learning in Medicine and More

Vijay Pande, David Clark

Interview, Fireside Chat

Andreessen Horowitz is distinguishing its bio-investing strategy by applying software methodologies and machine learning to traditional biological challenges, specifically targeting digital therapeutics, computational medicine, and cloud biology infrastructure. This approach leverages hybrid founders with dual expertise in computer science and biology to de-risk drug development, enabling scalable solutions that integrate with existing healthcare systems while projecting software-like returns. By transforming healthcare from acute intervention to preventative maintenance through advanced data analytics, the firm aims to secure exit multiples significantly higher than those typical of conventional life sciences ventures.